

Talius Group September 2026 Quarterly Report

15 October 2026

HIGHLIGHTS

- **Positive operating cash flow of \$242k for the quarter, with cash increasing by \$151k to \$4.672m at 30 September 2026**
- **Operating revenue (unaudited) of \$1.927m, up approximately 47% on the prior corresponding quarter and up 5% on the June 2026 quarter**
- **Active subscriptions increased to 53,958, up 7.7% year-on-year (YoY) and 1.4% quarter-on-quarter (QoQ)**
- **Annualised Recurring Revenue (ARR) increased to approximately \$3.5m, up 9.2% YoY and 7.7% QoQ**
- **Approximately \$2.5m of additional contract and purchase order value secured through expanded relationships with Adventist Retirement Plus and Hato Hone St John, carrying approximately \$190k of associated annual recurring revenue as deployments are activated**
- **Contracted deployments progressed, with Adventist Retirement Plus Stage 1 completed and further Adventist, Longridge and NZ projects underway**
- **Signed an integration agreement with UK digital care management provider Nourish Care, strengthening Talius' UK proposition and interoperability**
- **Subsequent to quarter end, Talius partnered with Health Generation to take CareGen Intelligence™ to the Australian aged care market**

Talius Group Limited ("Talius" or "the Company") (ASX: TAL) is pleased to provide the following activities and business update alongside its Appendix 4C – Quarterly Cash Flow Report for the quarter ended 30 September 2026 ("the quarter").

The September quarter delivered further progress against Talius' strategy to build a scalable, higher-margin recurring revenue business.

The Company achieved positive operating cash flow of \$242k for the quarter, increased active subscriptions to 53,958 and grew Annualised Recurring Revenue ("ARR") to approximately \$3.5m.

Commercial activity during the period was characterised by further expansion within established enterprise customer relationships. Following earlier deployments, Talius secured an additional \$1.65m Statement of Work with Adventist Retirement Plus and an approximately \$850k follow-on order from Hato Hone St John in New Zealand. Together, these engagements carry approximately \$190k of associated ARR as the relevant deployments are completed and activated.

Talius also advanced previously contracted projects while strengthening its commercial capability, strategic partnerships and platform interoperability.

Sales and Commercial Activity

Adventist aged care and retirement network

Talius continued to expand its relationship with the Adventist aged care and retirement network during the quarter.

On 3 August 2026, the Company announced a new \$1.65 million Statement of Work with Adventist Retirement Plus ("ARP"), covering two new Queensland facilities at Caloundra and Capricorn and a second-stage deployment at Victoria Point.

The agreement comprises approximately \$1.25m of hardware revenue and \$404k of contracted software revenue over an initial three-year period, equivalent to approximately \$135k of ARR. The deployments incorporate nurse call, sleep monitoring and Real-Time Location System solutions.

During the quarter:

- ARP Stage 1 deployments at Melody Park and Victoria Point were completed
- ARP Stage 2 works at Victoria Point, Capricorn and Caloundra commenced and are underway
- The Seventh-Day Adventist Aged Care deployment at Alstonville progressed in the period
- The Avondale deployment remains scheduled to commence during FY27

The successive Adventist engagements demonstrate Talius' strategy of establishing enterprise commercial frameworks and then expanding through additional sites and Statements of Work.

Across the announced Adventist engagements, Talius has secured approximately \$3.36m of contract value across six site or facility deployments, carrying approximately \$278k of associated ARR.

Hato Hone St John

On 10 August 2026, Talius announced an approximately A\$850k expansion order from Hato Hone St John ("HHSJ") in New Zealand.

The order comprises 4,000 additional Lifepod units and 4,000 Emergency Personal Pendants. The additional Lifepod deployment is expected to contribute approximately A\$55k of ARR as devices are progressively activated.

The order follows previous successful HHSJ deployments and represents further expansion of one of Talius' largest enterprise customer relationships. Emergency Personal Pendant deliveries are scheduled for October 2026, with Lifepod deliveries expected to commence in November and continue progressively thereafter.

The Company views HHSJ as a live example of its international expansion model, where initial hardware deployments create an installed base from which recurring platform revenue can grow as devices are commissioned.

Longridge Aged Care

The deployment for Longridge Aged Care in South Australia progressed during the quarter.

The three-year engagement, announced on 20 July 2026 and previously disclosed as a subsequent event in the June quarterly report, has a total contract value of approximately \$319k, comprising approximately \$264k of hardware and \$56k of software revenue over the three-year term.

The project adds to Talius' South Australian customer base and contributes approximately \$18,600 of annual software revenue as services are activated.

Subsequent to Quarter End – ACH Group

Talius secured a five-year agreement with ACH Group valued at approximately \$475,000 to transition its existing Real-Time Location System (RTLS) to the Talius platform. The agreement incorporates recurring weekly charges for equipment and software licensing, delivering an uplift of approximately \$75,000 in Annual Recurring Revenue (ARR). The solution is designed to improve clinical outcomes through greater accuracy, streamlined workflows and proven hardware.

Deployment will commence in Q4 FY2026, with completion expected during Q2 FY2027. The agreement demonstrates Talius' ability to replace incumbent technology solutions while expanding its recurring revenue base.

Subsequent to Quarter End – Pennwood Aged Care

Talius executed a Master Services Agreement (MSA) and Service Level Agreement (SLA) with existing customer Pennwood Aged Care for the installation of a nurse call system at its 37-bed McLaren Vale facility in South Australia.

The agreement has a total contracted value of approximately \$109,000, comprising \$77,000 in hardware revenue and \$32,000 in software revenue over three years, representing approximately \$10,600 in Annual Recurring Revenue (ARR). The engagement further expands Talius' South Australian customer base and supports continued growth in recurring software revenue.

Strategic Partnerships and Integrations

Nourish Care (UK)

Talius also signed an integration agreement with UK digital care management provider Nourish Care during the quarter.

The agreement provides a framework for integration between the Talius platform and Nourish's digital care management environment, enabling mutual customers to connect Talius-generated information with existing care management workflows, subject to completion of the agreed integration, testing and approval processes.

The integration supports Talius' UK strategy by improving interoperability with established care management systems and reducing technology friction for providers adopting the Talius platform.

Subsequent to quarter end – CareGen Intelligence

On 1 October 2026, Talius entered into a binding commercial partnership with Australian aged care consultancy Health Generation to take the co-branded CareGen Intelligence™ solution to market.

CareGen combines Talius' sensor technology, Care Intelligence platform and reporting capabilities with Health Generation's registered-nurse-led clinical support.

Health Generation will lead client acquisition and clinical service delivery, while Talius will provide the technology platform, hardware, implementation and ongoing platform support. The partnership provides Talius with an additional route to market and the potential for upfront technology revenue and recurring platform subscription revenue as deployments are secured.

The partnership has an initial objective to engage three new customer sites and commission one pilot during the first 12-month measurement period, outside Talius' existing installed customer base.

Subscriptions and recurring revenue

At 30 September 2026, Talius had 53,958 active subscriptions, representing growth of 1.4% during the quarter and 7.7% YoY.

Active ARR increased to approximately \$3.5m, representing growth of 7.7% QoQ and 9.2% YoY.

The increase in ARR reflects both continued subscription growth and a pricing increase implemented from 1 July 2026 across the majority of the Company's customer base.

The ARP expansion and Hato Hone St John order announced during the quarter carry approximately \$190k of associated annual recurring revenue, which is expected to be progressively reflected in active ARR as the relevant deployments are completed and services are activated.

Growing higher-margin recurring revenue remains central to Talius' strategy. The Company's commercial model uses hardware deployments to establish the technology and data infrastructure from which recurring software subscriptions, additional modules and further site deployments can grow over time. This approach was described in the Company's HY26 results as a key element of its strategy to improve margins and move toward sustainable cash generation.

People and commercial capability

During the quarter, Talius appointed experienced aged care leader Marcus Riley as Strategic Adviser. Mr Riley is supporting management across go-to-market strategy, sector partnerships and market positioning across residential aged care, retirement living and home care.

Founder Graham Russell stepped down from the Talius Board during September, with the Company's strategy and operating priorities remaining unchanged.

On 28 September 2026, the Company announced the appointment of Jamie Straw as Head of Sales, with Mr Straw commencing on 12 October 2026. Mr Straw brings more than two decades of sales and business development experience, including significant healthcare technology and aged care experience, and will lead sales activities across all Talius markets.

Subsequent to quarter end, Arun Malarazhagan moved from General Manager, Operations to Chief Operating Officer, effective 1 October 2026, strengthening operational leadership as the Company progresses a growing deployment pipeline.

Financial Position

Talius recognised unaudited operating revenue of \$1.927m for the quarter, representing an increase of approximately 47% from \$1.310m in the September 2025 quarter and approximately 5% from \$1.828m in the June 2026 quarter.

Cash receipts from customers totalled \$2.179m during the quarter.

Net cash generated from operating activities was \$242k, compared with a \$420k operating cash outflow in the June quarter. For the nine months to 30 September 2026, net operating cash outflow was approximately \$33k.

After investing cash outflows of \$25k and financing cash outflows of \$66k, cash increased by \$151k during the quarter.

At 30 September 2026, the Company held cash and cash equivalents of \$4.672m, compared with \$4.521m at 30 June 2026.

The positive operating cash result represents further progress against the Company's stated objective of building a scalable business with sustainable cash generation. At HY26, Talius had already reduced operating cash outflow to \$276k for the six-month period, compared with \$1.80m in the prior corresponding period.

Related party payments during the quarter totalled \$247k, as detailed in Section 6 of the accompanying Appendix 4C, and represented director fees.

Outlook

Talius remains focused on converting its contracted pipeline into completed deployments, customer receipts and recurring software revenue.

Priorities for the December 2026 quarter include:

- Progress the ARP Stage 2 deployments at Victoria Point, Capricorn and Caloundra
- Continue the Northern NSW Adventist deployment and prepare for commencement of Avondale during FY27
- Progress the South Australian deployments (Longridge, ACH and Pennwood)
- Commence delivery of the additional Hato Hone St John devices and progressively activate the associated recurring revenue
- Progress the CareGen commercial rollout and initial customer engagement
- Maintain disciplined working capital management and continue growing the recurring software revenue base

The Company continues to progress several additional commercial opportunities across its core markets. Timing remains subject to customer procurement, approval and contracting processes, and Talius will provide further updates as opportunities convert into binding engagements.

Commenting on the quarter, Talius Managing Director and CEO Pat Howard said:

"The September quarter was another important step forward for Talius. We returned to positive operating cash flow, grew ARR to around \$3.5 million and continued to expand with enterprise customers that already know the platform."

"The follow-on work with Adventist and Hato Hone St John shows the pattern we want to keep building – establish the relationship, deliver well and then expand across more sites and services."

"We have also strengthened our commercial team and opened additional routes to market through partnerships and integrations such as Health Generation and Nourish."

"Our focus from here is execution. Our job now is to turn that commercial momentum into active subscriptions, recurring revenue and sustainable cash generation."

This announcement has been authorised for release by the Board of Directors of Talius Group Ltd.

Investor Enquiries:

Tim Dohrmann

NWR Communications

+61 468 420 846

investors@talius.com.au

More on TALIUS

[Investor Centre](#)

[About Us](#)

[News](#)

About Talius Group Limited (ASX: TAL)

Talius provides a suite of technology enabled care solutions to the aged and disability sectors across multiple verticals, including retirement living, residential aged care, home, and community settings to improve the quality of life, later in life.

Talius' Software as a Service (SaaS) data analytics platform Talius Smart Care combines smart sensors with AI machine learning that delivers automated actions. Talius links awareness, analysis, and action through one platform allowing the care model to move from spot check care to sense-respond care. Nursing staff can switch their focus from data collection to building a human connection. Most importantly, residents benefit from a new era of autonomy and dignity.

Talius helps protect and connect our elderly and people with disabilities with a scalable healthcare technology platform integrated with leading third-party providers to ensure end-to-end solutions for Connected Health.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

TALIUS GROUP LIMITED

ABN

62 111 823 762

Quarter ended ("current quarter")

30 SEPTEMBER 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	2,179	5,592
1.2	Payments for		
	(a) research and development	(62)	(176)
	(b) product manufacturing and operating costs	(1,104)	(2,547)
	(c) advertising and marketing	(55)	(166)
	(d) property expenses	(6)	(19)
	(e) staff costs	(904)	(2,672)
	(f) administration and corporate costs	(146)	(425)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	26	81
1.5	Interest and other costs of finance paid	(8)	(23)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	322	322
1.8	Other income	-	-
1.9	Net cash from / (used in) operating activities	242	(33)
2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) software, plant and equipment	(25)	(38)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(25)	(38)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Share buyback	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(1)	(3)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(31)	(76)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Repayment of lease liabilities	(34)	(97)
3.10	Net cash from / (used in) financing activities	(66)	(176)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,521	4,919
4.2	Net cash from / (used in) operating activities (item 1.9 above)	242	(33)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(25)	(38)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(66)	(176)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	4,672	4,672

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4,672	4,521
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,672	4,521

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	247
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> Director fees and Managing Director salary & superannuation: \$247,123		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other – Insurance premium funding	31	31
7.4 Total financing facilities	31	31
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
Insurance premium funding facility provided by Hunter Premium Funding. The amount is unsecured, repayable in monthly instalments by February 2027 and bears interest at 12.4% per annum.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	242
8.2 Cash and cash equivalents at quarter end (item 4.6)	4,672
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	4,672
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 15 October 2026

Authorised by: The Board of Directors of Talius Group Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.